EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

Robert Pirker, Kenneth J. O’Byrne, Joachim von Pawel et al.|The Lancet Oncology|2011

Cited by 574